|Bid||1,290.00 x 175400|
|Ask||1,310.00 x 417900|
|Day's Range||1,287.83 - 1,300.83|
|52 Week Range||1,270.00 - 1,724.50|
|PE Ratio (TTM)||27.38|
|Earnings Date||Feb 7, 2018|
|Forward Dividend & Yield||1.01 (5.14%)|
|1y Target Est||1,549.93|
GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.
First targeted treatment approved for this rare eosinophil-driven disease, following FDA Priority Review LONDON , Dec. 12, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that ...
Shares of Gilead Sciences (GILD) are rising Wednesday, helped by a bullish note from Credit Suisse, which argues that its HIV treatment Bictegravir could be a launch that will become "the greatest ...
GlaxoSmithKline’s (GSK) Vaccines business reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.
GlaxoSmithKline is using artificial intelligence to learn why certain HIV patients drop out of treatment. "The only clues that exist are in unstructured types of data," such as doctor's notes, ...
GlaxoSmithKline’s (GSK) Vaccines segment reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.
GlaxoSmithKline's (GSK) 3Q17 revenues of ~7.8 billion pounds represented 4.0% growth compared to its 3Q16 revenues of ~7.5 billion pounds.
In 3Q17, GlaxoSmithKline (GSK) surpassed Wall Street analysts’ estimates for its earnings per share. GSK reported revenues of ~7.8 billion pounds, missing the estimate of 7.9 billion pounds.
On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.
Novartis saw revenues of ~$12.4 billion and EPS of $1.29 for 3Q17, which represents a 2% YoY rise, compared with its revenues of ~$12.1 billion in 3Q16.
Glaxo (GSK) announces start of a large late-stage African study on an experimental long-acting injection for the prevention of HIV.
Glaxo (GSK) and partner Medicines for Malaria Venture filed a new drug application (NDA) with the FDA for single-dose anti relapse medicine for malaria.
Glaxo (GSK) and partner Pfizer's ViiV Healthcare commences a phase III study on combo regimen of cabotegravir and rilpivirine for treatment of adults with virally suppressed HIV-1 infection.
Most drug companies with a larger market cap have seen their share price rising this year. However, a couple of large-cap pharma companies have witnessed a downside this year.
The Zacks Analyst Blog Highlights: Union Pacific, Alibaba, GlaxoSmithKline, eBay and Welltower
As HIV and AIDS have limited medical cure but huge medical need, we see how different companies are trying to tap into this huge market.
Key highlights this week include the FDA approval of GlaxoSmithKline (GSK) and J&J's new HIV drug and study data from Roche.